About Fate Therapeutics
Fate Therapeutics, Inc. (Fate Therapeutics) is a clinical-stage biopharmaceutical company. The Company is engaged in development of programmed cellular immunotherapies for cancer and immune disorders. The Company's cell therapy pipeline consists of immuno-oncology programs, including cancer immunotherapies derived from engineered induced pluripotent cells, and immuno-regulatory programs, including hematopoietic cell immunotherapies for protecting the immune system of patients undergoing hematopoietic cell transplantation and for suppressing autoimmunity. Its lead clinical program is ProTmune, which is a programmed immuno-regulatory cell therapy. The Company programs immune cells, such as CD34+ cells, Natural Killer (NK) cells and T cells, by utilizing its cell programming approach. Its adoptive cell therapy programs are based on the Company's ex vivo cell programming approach, which it applies to modulate the therapeutic function and direct the fate of immune cells.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biotechnology
- Sub-Industry: N/A
- Exchange: NASDAQ
- Symbol: FATE
- Previous Close: $4.02
- 50 Day Moving Average: $3.10
- 200 Day Moving Average: $2.82
- 52-Week Range: $34,148,000.00 - $1.47
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -4.24
- P/E Growth: 0.00
- Market Cap: $138.98M
- Outstanding Shares: 34,148,000
- Beta: 1.2
- Net Margins: -740.69%
- Return on Equity: -112.48%
- Return on Assets: -58.58%
Companies Related to Fate Therapeutics:
- Debt-to-Equity Ratio: 0.18%
- Current Ratio: 3.23%
- Quick Ratio: 3.23%
What is Fate Therapeutics' stock symbol?
Fate Therapeutics trades on the NASDAQ under the ticker symbol "FATE."
Where is Fate Therapeutics' stock going? Where will Fate Therapeutics' stock price be in 2017?
6 equities research analysts have issued 12-month price targets for Fate Therapeutics' shares. Their predictions range from $4.00 to $9.00. On average, they expect Fate Therapeutics' share price to reach $6.40 in the next year.
When will Fate Therapeutics announce their earnings?
Fate Therapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, March, 1st 2017.
Who owns Fate Therapeutics stock?
Fate Therapeutics' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Franklin Resources Inc. (17.80%), FMR LLC (12.86%), Kingdon Capital Management L.L.C. (7.66%) and Renaissance Technologies LLC (0.61%). Company insiders that own Fate Therapeutics stock include Chris Storgard and William H Rastetter.
Who sold Fate Therapeutics stock? Who is selling Fate Therapeutics stock?
Fate Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including Kingdon Capital Management L.L.C..
Who bought Fate Therapeutics stock? Who is buying Fate Therapeutics stock?
Fate Therapeutics' stock was purchased by a variety of institutional investors in the last quarter, including Franklin Resources Inc., FMR LLC and Renaissance Technologies LLC. Company insiders that have bought Fate Therapeutics stock in the last two years include Chris Storgard and William H Rastetter.
How do I buy Fate Therapeutics stock?
Shares of Fate Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Fate Therapeutics stock cost?
One share of Fate Therapeutics stock can currently be purchased for approximately $4.07.